136 related articles for article (PubMed ID: 37552603)
1. ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.
Tabrizian N; Nouruzi S; Cui CJ; Kobelev M; Namekawa T; Lodhia I; Talal A; Sivak O; Ganguli D; Zoubeidi A
Cell Rep; 2023 Aug; 42(8):112937. PubMed ID: 37552603
[TBL] [Abstract][Full Text] [Related]
2. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.
Nouruzi S; Ganguli D; Tabrizian N; Kobelev M; Sivak O; Namekawa T; Thaper D; Baca SC; Freedman ML; Aguda A; Davies A; Zoubeidi A
Nat Commun; 2022 Apr; 13(1):2282. PubMed ID: 35477723
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
[TBL] [Abstract][Full Text] [Related]
6. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
7. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
8. Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM; Huang H
Asian J Androl; 2019; 21(3):241-248. PubMed ID: 29900883
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
10. New approaches to targeting the androgen receptor pathway in prostate cancer.
Velho PI; Bastos DA; Antonarakis ES
Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
[TBL] [Abstract][Full Text] [Related]
11. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Davies AH; Beltran H; Zoubeidi A
Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
[TBL] [Abstract][Full Text] [Related]
12. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
13. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
[TBL] [Abstract][Full Text] [Related]
14. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Fan L; Gong Y; He Y; Gao WQ; Dong X; Dong B; Zhu HH; Xue W
Oncogene; 2023 Feb; 42(8):559-571. PubMed ID: 36544044
[TBL] [Abstract][Full Text] [Related]
15. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.
Zarif JC; Miranti CK
Cell Signal; 2016 May; 28(5):348-356. PubMed ID: 26829214
[TBL] [Abstract][Full Text] [Related]
16. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
17. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer.
Kyprianou N; Lucien F
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769075
[TBL] [Abstract][Full Text] [Related]
18. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S; Wang C; Wang Y; Xu Y; Li X; Johnson NA; Mukherji A; Lo UG; Xu L; Gonzalez J; Metang LA; Ye J; Tirado CR; Rodarte K; Zhou Y; Xie Z; Arana C; Annamalai V; Liu X; Vander Griend DJ; Strand D; Hsieh JT; Li B; Raj G; Wang T; Mu P
Nat Cancer; 2022 Sep; 3(9):1071-1087. PubMed ID: 36065066
[TBL] [Abstract][Full Text] [Related]
19. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
20. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
